AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	3911	25122-57-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: eumovate kindavate clobetasone butyrate 21-Chloro-11-dehydrobetamethasone clobetasone 17-butyrate	Molecular weight: 478.99 Formula: C26H32ClFO5 CLOGP: 4.21 LIPINSKI: 0 HAC: 5 HDO: 0 TPSA: 77.51 ALOGS: -5.44 ROTB: 6

Molecule

Description

Molfile Inchi Smiles

Synonyms:

eumovate
kindavate
clobetasone butyrate
21-Chloro-11-dehydrobetamethasone
clobetasone 17-butyrate

Molecular weight: 478.99
Formula: C26H32ClFO5
CLOGP: 4.21
LIPINSKI: 0
HAC: 5
HDO: 0
TPSA: 77.51
ALOGS: -5.44
ROTB: 6

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	3.680		Moderate	0.69
caco2-efflux	Caco-2 efflux ratio (BA/AB)	1.324		Moderate	0.69
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	74.302	10^-6 cm/s	Moderate	0.69
dh-clint	Dog hepatocyte intrinsic clearance	84.918	uL/min/10^6 cells	Moderate	0.69
dppb	Dog plasma protein binding (% unbound)	1.840	%	Moderate	0.69
fcs-ppb	Fetal calf serum protein binding (% unbound)	3.930	%	Moderate	0.69
herg	hERG pIC50	4.919	pIC50	Moderate	0.69
hh-clint	Human hepatocyte intrinsic clearance	108.643	uL/min/10^6 cells	Moderate	0.69
hlm-clint	Human liver microsomal intrinsic clearance	236.592	uL/min/mg protein	Moderate	0.69
hppb	Human plasma protein binding (% unbound)	2.190	%	Moderate	0.69
kinase-safety-class	ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,TTK,ZAP70	42
kinase-selectivity-class	AXL,GRK2,MAP2K6	3
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	2.328		Moderate	0.69
mh-clint	Mouse hepatocyte intrinsic clearance	184.077		Moderate	0.69
mppb	Mouse plasma protein binding (% unbound)	2.150		Moderate	0.69
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	8.072		Moderate	0.69
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	4.880	%	Moderate	0.69
rh-clint	Rat hepatocyte intrinsic clearance	152.055	uL/min/10^6 cells	Moderate	0.69
rh-fuinc	Rat hepatocyte fraction unbound in incubation	18.990	%	Moderate	0.69
rppb	Rat plasma protein binding (% unbound)	1.630	%	Moderate	0.69
solubility-dd	Solubility at pH 7.4 in DMSO	5.248	uM	Moderate	0.69

Approvals:

Date	Agency	Company	Orphan
None	PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Steroid withdrawal syndrome	95.98	33.71	16	1952	660	90625819
Skin weeping	73.29	33.71	16	1952	2784	90623695
Skin exfoliation	68.19	33.71	32	1936	67881	90558598
Skin burning sensation	42.51	33.71	16	1952	19595	90606884
Pruritus	35.98	33.71	51	1917	541474	90085005
Eczema	35.55	33.71	19	1949	52851	90573628
Catarrh	35.40	33.71	8	1960	1626	90624853
Medication error	34.55	33.71	22	1946	84630	90541849
Rash erythematous	34.49	33.71	20	1948	65084	90561395
Skin atrophy	34.37	33.71	10	1958	5519	90620960
Burns second degree	33.87	33.71	8	1960	1972	90624507

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Catarrh	236.75	105.71	63	3852	5923	42611497
Burns second degree	235.61	105.71	63	3852	6033	42611387
Steroid dependence	229.51	105.71	63	3852	6659	42610761
Parosmia	221.11	105.71	63	3852	7628	42609792
Hypopnoea	219.59	105.71	63	3852	7819	42609601
Gingival pain	219.35	105.71	64	3851	8430	42608990
Systemic lupus erythematosus	213.45	105.71	64	3851	9260	42608160
Rhinitis	193.60	105.71	63	3852	11914	42605506
Cardiac murmur	189.61	105.71	63	3852	12712	42604708
Impaired work ability	180.92	105.71	60	3855	12031	42605389
Swollen tongue	172.46	105.71	67	3848	21164	42596256
Bronchiectasis	172.07	105.71	64	3851	17955	42599465
Frequent bowel movements	164.86	105.71	65	3850	21342	42596078
Alcohol poisoning	164.75	105.71	50	3865	7524	42609896
Eczema	157.48	105.71	72	3843	34014	42583406
Colitis ulcerative	152.22	105.71	65	3850	26110	42591310
Impaired quality of life	148.80	105.71	54	3861	14123	42603297
Nightmare	148.38	105.71	63	3852	24949	42592471
Migraine	147.42	105.71	63	3852	25351	42592069
Tinnitus	145.95	105.71	65	3850	28873	42588547
Accidental overdose	144.05	105.71	64	3851	28266	42589154
Medication error	137.49	105.71	65	3850	33089	42584331
Tubulointerstitial nephritis	134.35	105.71	63	3852	31485	42585935
Dysgeusia	132.55	105.71	64	3851	34125	42583295
Vertigo	132.27	105.71	64	3851	34283	42583137
Stress	119.78	105.71	65	3850	44147	42573273
Palpitations	119.37	105.71	68	3847	50729	42566691
Arthritis	117.18	105.71	63	3852	42002	42575418
Rectal haemorrhage	112.78	105.71	65	3850	49541	42567879
Loss of personal independence in daily activities	109.87	105.71	64	3851	49752	42567668

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Catarrh	299.95	50.54	71	5757	7264	110576207
Burns second degree	296.22	50.54	71	5757	7662	110575809
Steroid dependence	289.80	50.54	71	5757	8398	110575073
Hypopnoea	268.98	50.54	71	5757	11309	110572162
Parosmia	258.65	50.54	71	5757	13109	110570362
Gingival pain	250.66	50.54	72	5756	15664	110567807
Rhinitis	221.02	50.54	71	5757	22474	110560997
Cardiac murmur	214.86	50.54	71	5757	24557	110558914
Bronchiectasis	198.48	50.54	74	5754	36419	110547052
Impaired work ability	198.20	50.54	68	5760	26351	110557120
Swollen tongue	194.73	50.54	84	5744	60278	110523193
Alcohol poisoning	192.84	50.54	52	5776	8968	110574503
Nightmare	186.77	50.54	72	5756	38791	110544680
Eczema	180.20	50.54	84	5744	72209	110511262
Impaired quality of life	167.34	50.54	62	5766	29955	110553516
Tubulointerstitial nephritis	166.76	50.54	73	5755	54211	110529260
Accidental overdose	163.44	50.54	71	5757	51763	110531708
Tinnitus	162.27	50.54	74	5754	60466	110523005
Medication error	150.27	50.54	84	5744	105282	110478189
Dysgeusia	149.03	50.54	73	5755	69912	110513559
Frequent bowel movements	147.65	50.54	73	5755	71317	110512154
Colitis ulcerative	145.00	50.54	74	5754	77289	110506182
Vertigo	139.72	50.54	75	5753	86795	110496676
Stress	121.02	50.54	73	5755	105275	110478196
Haematochezia	119.83	50.54	75	5753	115449	110468022
Rectal haemorrhage	112.37	50.54	73	5755	119760	110463711
Palpitations	109.23	50.54	80	5748	159132	110424339
Deep vein thrombosis	104.43	50.54	74	5754	139813	110443658
Loss of personal independence in daily activities	95.31	50.54	72	5756	149948	110433523
Arthritis	92.50	50.54	74	5754	167512	110415959
Cerebrovascular accident	85.35	50.54	73	5755	181211	110402260
Migraine	84.66	50.54	71	5757	171581	110411890
Adverse drug reaction	83.77	50.54	58	5770	105501	110477970
Inappropriate schedule of product administration	79.96	50.54	74	5754	203563	110379908
Rash	78.24	50.54	148	5680	820816	109762655
Pulmonary embolism	74.81	50.54	73	5755	214401	110369070
Steroid withdrawal syndrome	70.69	50.54	15	5813	930	110582541
COVID-19	64.93	50.54	72	5756	244988	110338483
Somnolence	64.79	50.54	79	5749	297370	110286101
Systemic lupus erythematosus	64.44	50.54	73	5755	254265	110329206
Intentional product use issue	62.54	50.54	71	5757	247835	110335636
Skin weeping	54.59	50.54	16	5812	3719	110579752
Depression	53.06	50.54	74	5754	317261	110266210

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D07AB01	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, PLAIN Corticosteroids, moderately potent (group II)
ATC	S01BA09	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Corticosteroids, plain
ATC	S01CA11	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION Corticosteroids and antiinfectives in combination
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones

Related Drugs by ATC class:

D07AB Corticosteroids, moderately potent (group II) 12 drugs

alclometasone dipropionate clocortolone pivalate desonide dexamethasone flumetasone fluocortin butyl fluorometholone fluperolone fluprednidene hydrocortisone butyrate hydrocortisone probutate triamcinolone

S01BA Corticosteroids, plain 15 drugs

alclometasone dipropionate betamethasone clobetasol propionate desonide dexamethasone difluprednate fluocinolone acetonide fluorometholone formocortal hydrocortisone loteprednol etabonate medrysone show all 15 →

S01CA Corticosteroids and antiinfectives in combination 11 drugs

betamethasone chloroprednisone dexamethasone fludrocortisone acetate fluocinolone acetonide fluocortolone fluorometholone hydrocortisone loteprednol etabonate methylprednisolone prednisolone

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Atopic dermatitis	indication	24079001	DOID:3310
Eczema	indication	43116000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST				KEGG DRUG	KEGG DRUG

External reference:

ID	Source
D01273	KEGG_DRUG
C0055896	UMLSCUI
CHEBI:31415	CHEBI
CHEMBL2308885	ChEMBL_ID
C010893	MESH_SUPPLEMENTAL_RECORD_UI
8U0H6XI6EO	UNII
71386	PUBCHEM_CID
DB13158	DRUGBANK_ID
108074	RXNORM
003809	NDDF
003810	NDDF
116576003	SNOMEDCT_US
395963000	SNOMEDCT_US
395967004	SNOMEDCT_US
C0360518	UMLSCUI
54063-32-0	SECONDARY_CAS_RN
71387	PUBCHEM_CID
9088	IUPHAR_LIGAND_ID
3155	INN_ID
LT69WY1J6D	UNII
8U0H6XI6EO	INXIGHT DRUGS
LT69WY1J6D	INXIGHT DRUGS

Pharmaceutical products:

None

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

clobetasone butyrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: